Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharma Tech Industries Selected to Manufacture Innovative Nasal Delivery System

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Start-to-finish services on behalf of OptiNose include capsule filling, medical device assembly, pouching, packaging and palletizing.

Pharma Tech Industries (PTI) has been selected to handle filling, assembly and packaging services for a migraine relief medication administered through an innovative new method: a breath-powered nasal delivery system. The drug itself is powder-based, and PTI was chosen for this initiative – which will start as developmental, supporting FDA submission for approval and will continue into commercial –due to the company’s experience handling a broad range of powders, and its ability to vertically integrate the entire production process.

The OptiNose delivery system employs a novel means of easily administering drugs deep into the nasal cavity, enabling the treatment of both local and systemic diseases. The new technology offers a much-needed alternative to existing, poor-performing nasal sprays, as well as to tablets and injections (see Page 2 for details). OptiNose has completed Phase III development for a Sumatriptan Succinate medicine that, when taken using its patented device, is expected to shorten the timeframe for relief from migraines when compared to widely used oral migraine medications.

Pharma Tech Industries will play a critical, turn-key role in preparing OptiNose’s NDA batches over the coming months. Utilizing a Planeta Capsule Filler from leading equipment manufacturer MG2, PTI will fill low-dose capsules with dry powder medication, achieving tight weight tolerances at high commercial speeds. From there, the capsules will be loaded into special unit-dose cartridges. PTI will then pack each cartridge – along with the primary nosepiece and an instruction insert for the end-user – into individual cartons, where they are mechanically packed into cases and palletized for shipping.

“We chose Pharma Tech Industries as our CMO through a rigorous selection process that evaluated more than half a dozen potential candidates,” said Peter Miller, CEO of OptiNose. “We are working to bring a groundbreaking delivery system to market, and its commercial development depends upon a partner that can execute with excellence. We believe that Pharma Tech Industries is such a partner.”

“It is exciting to work so closely with the team at OptiNose, who have spearheaded the creation of a very promising new drug delivery system, and we are thankful for this opportunity,” said Tee Noland, Chairman of Pharma Tech Industries. “This project allows PTI to showcase the broad spectrum of capabilities that make us such an attractive option for our customers.”

A Promising Nasal Delivery System for Migraine Sufferers

Intranasal formulations of some triptans – including sumatriptan and zolmitriptan – were developed with the intent of achieving faster onset of action compared to tablets, and a more appealing delivery method than injections. Many patients have nausea and, even without nausea, gastric emptying is often delayed during migraine attacks. This is a key reason tablets may not be as fast and effective as other delivery methods.

Current nasal sprays deliver much of the dose to the anterior third of the nose in front of the nasal valve, where absorption is inefficient and where part of the dose is easily lost to “drip out.” The remainder passes along the floor of the nose to be swallowed, where it offers no advantage over standard oral delivery.

The OptiNose breath-powered, bi-directional™ delivery device simply and reliably delivers medication deep into the nasal cavity, while preventing initial deposition in the mouth and lungs. This has potential to greatly increase the efficiency of nasal absorption of medication while reducing the amount of drug that is swallowed. This new form of drug delivery means that even with a much lower dose, the new migraine product has potential to produce fast and effective pain relief.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!